TGF‐β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation

BACKGROUND: Secondary lymphedema is a common complication of cancer treatment, and previous studies have shown that the expression of transforming growth factor‐beta 1 (TGF‐β1), a pro‐fibrotic and anti‐lymphangiogenic growth factor, is increased in this disease. Inhibition of TGF‐β1 decreases the se...

Descripción completa

Detalles Bibliográficos
Autores principales: Baik, Jung Eun, Park, Hyeung Ju, Kataru, Raghu P., Savetsky, Ira L., Ly, Catherine L., Shin, Jinyeon, Encarnacion, Elizabeth M., Cavali, Michele R., Klang, Mark G., Riedel, Elyn, Coriddi, Michelle, Dayan, Joseph H., Mehrara, Babak J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160979/
https://www.ncbi.nlm.nih.gov/pubmed/35652284
http://dx.doi.org/10.1002/ctm2.758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160979/
https://www.ncbi.nlm.nih.gov/pubmed/35652284
http://dx.doi.org/10.1002/ctm2.758

Ejemplares similares